The company will engage in BIO One-on-One Partnering™ meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study ...

The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their ...

Boston Scientific said on Wednesday it will stop pursuing U.S. approval for its experimental heart device due to increased clinical and regulatory requirements.

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

British pharmaceutical company GSK(GSK) to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, for as much as $2 billion.

The agreement announced Wednesday brings GSK efimosfermin alfa, a Boston Pharmaceuticals drug that is ready for Phase 3 testing. In addition to metabolic dysfunction-associated steatohepatitis ...

MIAMI, FL / ACCESS Newswire / May 28, 2025 / MIRA Pharmaceuticals ... taking place in Boston, MA from June 16-19, 2025. The Company has a full schedule of BIO One-on-One Partnering™ meetings ...

GSK GSK0.38%increase; green up pointing triangle will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs. The British ...

The treatment, made by Boston Pharmaceuticals, is ready to enter the last stage of clinical tests, the UK drugmaker said Wednesday. The medicine could become a blockbuster, according to analysts ...